Francesco Caracciolo

Francesco Caracciolo

Auto-generated profile, based on publicly available information

Francesco Caracciolo

University of Pisa

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1994 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CFClodoveo Ferri
Clodoveo Ferri
FCFrancesco Caracciolo
Francesco Caracciolo
AZAnna Linda Zignego
Anna Linda Zignego
LCLuca La Civita
Luca La Civita
MMMonica Monti
Monica Monti
GPGiampiero Pasero
Giampiero Pasero

7 December 2011 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FMFrancesco Merli
Francesco Merli
SLStefano Luminari
Stefano Luminari
FIFiorella Ilariucci
Fiorella Ilariucci
MPMario Petrini
Mario Petrini
CVCarlo Visco
Carlo Visco
MFMassimo Federico
Massimo Federico

1 March 1997 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
AZA. L. Zignego
A. L. Zignego
CFC. Ferri
C. Ferri
CGC. Giannini
C. Giannini
LCL. La Civita
L. La Civita
GCG. Careccia
G. Careccia
PGP. Gentilini
P. Gentilini

7 December 2007 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MPMatteo Pelosini
Matteo Pelosini
Daniele FocosiDaniele Focosi
Daniele Focosi
FRFazzi Rita
Fazzi Rita
SGSara Galimberti
Sara Galimberti
FCFrancesco Caracciolo
Francesco Caracciolo
MPMario Petrini
Mario Petrini

2 November 2004 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GCGiulia Cervetti
Giulia Cervetti
SGSara Galimberti
Sara Galimberti
FAFrancesca Andreazzoli
Francesca Andreazzoli
RFRita Fazzi
Rita Fazzi
NCNadia Cecconi
Nadia Cecconi
MPMario Petrini
Mario Petrini

30 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SGSusanna Grassi
Susanna Grassi
FGFrancesca Guerrini
Francesca Guerrini
ECElena Ciabatti
Elena Ciabatti
RPRiccardo Puccetti
Riccardo Puccetti
SSSerena Salehzadeh
Serena Salehzadeh
SGSara Galimberti
Sara Galimberti
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) interfere with cellular metabolism contributing to oncogenesis. Mutations of IDH2 at R140 and R172 residues are observed in 20% of acute myeloid leukemias (AML), and the availability of the IDH2 inhibitor Enasidenib made IDH2 mutational screening a clinical need. The aim of this study was to set a new quantitative polymerase chain reaction (PCR) technique, the drop-off digital droplet PCR (drop-off ddPCR), as a sensitive and accurate tool for detecting IDH2 mutations. With this technique we tested 60 AML patients. Sanger sequencing identified 8/60 (13.5%) mutated cases, while ddPCR and the amplification refractory mutation system (ARMS) PCR, used as a reference technique, identified mutations in 13/60 (21.6%) cases. When the outcome of IDH2-mutated was compared to that of wild-type patients, no significant difference in terms of quality of response, overall survival, or progression-free survival was observed. Finally, we monitored IDH2 mutations during follow-up in nine cases, finding that IDH2 can be considered a valid marker of minimal residual disease (MRD) in 2/3 of our patients. In conclusion, a rapid screening of IDH2 mutations is now a clinical need well satisfied by ddPCR, but the role of IDH2 as a marker for MRD still remains a matter of debate.